CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← Viridian Therapeutics, Inc. (VRDN) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

Viridian Therapeutics, Inc. (VRDN)

Pharmaceutical Preparations · market cap $2.4B · as of 2026-07-17

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
None scheduled
Pipeline
6
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Viridian Therapeutics (VRDN) is a clinical-stage pharma focused exclusively on Thyroid Eye Disease (TED), with two Phase 3 assets: veligrotug (VRDN-001) and VRDN-003. The company received a positive PDUFA outcome on 2026-07-02, indicating regulatory approval of its lead asset, while holding $176.3M in cash against a ~4.4-month runway at current burn rates.
The catalyst path

No upcoming catalysts in our calendar.

Pipeline
AssetPhaseIndication
VRDN-001Phase 3Thyroid Eye Disease
Intervention/TreatmentPhase 3Thyroid Eye Disease
VRDN-001 Phase 3 Cohort (THRIVE)Phase 3Thyroid Eye Disease
Veligrotug (VRDN-001)Phase 3Thyroid Eye Disease
VRDN-003Phase 3Thyroid Eye Disease
VeligrotugPhase 3Thyroid Eye Disease
Price & technical context
3-month
+29.4%
6-month
+77.7%
12-month
+10.0%
52-wk range
$13.30–$33.78
vs 50-day MA
+34.6%
vs 200-day MA
+46.1%
Realized vol
74.6%
Max drawdown
-60.6%

Daily closes through 2026-11-19. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for VRDN (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 6 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.